



Name	Gi-Ae Kim
Affiliation	Kyung Hee University School of Medicine
Country	Korea
Major Field	Hepatology

Educational Background

2002-2008, Hanyang University College of Medicine, Seoul, Korea

2012, Master's degree of Medicine, University of Ulsan Collage of Medicine

2018, Doctor's degree of Medicine, University of Ulsan Collage of Medicine

Professional Experience

2009-2013, Internship & Residency of internal Medicine, Asan Medical Center, Seoul, Korea

2013-2014, Clinical Fellow, Gastroenterology & Hepatology, Asan Medical Center, Seoul, Korea

2015-2018, Clinical Professor, Health Screening and Promotion Center, Asan Medical Center, Seoul, Korea

2019.3-2021.8 Clinical Professor, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea

2021.9- Assistant Professor, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea

2025.9- Associate Professor, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea

Main Scientific Publications

1. Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B: A Multinational Study for the Development and External Validation of a New Prognostic Model. **Kim GA**, Lim YS, Han S, Choi GH, Choi WM, Choi J, Sinn DH, Paik YH, Lee JH, Lee YB, Cho JY, Heo NY, Yuen MF, Wong VW, Chan SL, Yang HI, Chen CJ.

Ann Intern Med. 2024 Oct;177(10):1308-1318. doi: 10.7326/M24-0384. Epub 2024 Sep 17.

2. Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study.

Park Y, Jung J, Han S, **Kim GA**.

Aliment Pharmacol Ther. 2024 Dec;60(11-12):1599-1608. doi: 10.1111/apt.18286. Epub 2024 Sep 20.

3. Non-linear association between liver fibrosis scores and viral load in patients with chronic hepatitis B.

Kim GA, Choi SW, Han S, Lim YS.

Clin Mol Hepatol. 2024 Oct;30(4):793-806. doi: 10.3350/cmh.2024.0252. Epub 2024 Jul 19.

4. A risk prediction model for hepatocellular carcinoma in non-alcoholic fatty liver disease without cirrhosis: HCC prediction for non-cirrhotic NAFLD.

Kim GA, Park Y, Oh SJ, Jung J, Han S, Chang HS, Park SW, Kim TH, Park HW, Choe J, Kim J, Lee HC.

Liver Int. 2024 Mar;44(3):738-748. doi: 10.1111/liv.15819. Epub 2023 Dec 18.

5. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study.

Kim GA, Jeong S, Jang H, Lee DH, Joo SK, Kim W.

Liver Cancer. 2023 Dec 22;13(4):426-437. doi: 10.1159/000535943. eCollection 2024 Aug.

6. Critical appraisal of metabolic dysfunction-associated steatotic liver disease: Implication of Janus-faced

SIDDS 2026



Date **Apr. 18.(Sat)-19.(Sun) 2026**

Venue **Grand Walkerhill Seoul, Korea**

Navigating Towards the Optimum Digestive Care : Beyond Linguistic Barriers

modernity.

Kim GA, Moon JH, Kim W.

Clin Mol Hepatol. 2023 Oct;29(4):831-843. doi: 10.3350/cmh.2023.0277. Epub 2023 Aug 25.

7. A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ALS-L1023 in Non-Alcoholic Fatty Liver Disease.

Kim GA, Cho HC, Jeong SW, Kang BK, Kim M, Jung S, Hwang J, Yoon EL, Jun DW.

Pharmaceuticals (Basel). 2023 Apr 20;16(4):623. doi: 10.3390/ph16040623.

